Levemir vs. Lantus - TuDiabetes
Links shared publicly online about this topic.
- 410total visits
Levemir vs. Lantus - TuDiabetes
View full resource at tudiabetes.org
Tags: Diabetes, Diabetes Type 1 Medication, Diabetes Type 2 Medication, Diabetes Medication, Type 1 Diabetes, Relationship, Lantus
Most Recently Shared on March 26, 2011 at 11:59 pm By:
Type 1 diabetes: Levemir vs. Lantus: My 12 year old son had his first follow-up with his endo yesterday after b... http://tud4.us/g10jWI
Dr. Mintz' Blog: More Evidence that Lantus Causes Cancer
drmintz.blogspot.com — “A physician's perspective on recent medical items from the news and media” View full resource at drmintz.blogspot.com
Most Recently Shared on December 7, 2011 at 1:42 pm By:
drmintz Internist, Physician, and Doctor
More Evidence that Lantus Causes Cancer: There is a new study reported in Bloomberg this morning that Sanofi’s L... http://t.co/G8b1tcuf
Less Glycemic Variability, Better Patient Reported Outcomes With Lantus & Apidra
medicalnewstoday.com — “Less Glycemic Variability, Better Patient Reported Outcomes With Lantus & Apidra” View full resource at medicalnewstoday.com
Most Recently Shared on June 28, 2010 at 6:30 pm By:
Scott Strumello Patient Expert
Less Glycemic Variability, Better Patient Reported Outcomes With Lantus & Apidra http://bit.ly/bEyOGc
Long-acting insulin analogues in type 1 diabetes: No proof of additional benefit
physorg.com — “It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to ...” View full resource at physorg.com
Most Recently Shared on May 12, 2010 at 1:56 pm By:
PhysOrg Health News Health News
Long-acting insulin analogues in type 1 diabetes: No proof of additional benefit http://tw.physorg.com/192876972
Study: Sanofi’s Lantus Insulin Has Possible Cancer Link - Health Blog - WSJ
blogs.wsj.com — “The French drug giant, whose stock fell more than 7%, said "no definitive conclusions can be drawn" from the data.” View full resource at blogs.wsj.com
Most Recently Shared on June 26, 2009 at 11:38 pm By:
Study: Sanofi’s Lantus Insulin Has Possible Cancer Link http://bit.ly/vsR9k
Advertisement
